2015
DOI: 10.1007/s00253-015-6470-z
|View full text |Cite
|
Sign up to set email alerts
|

Quo vadis? The challenges of recombinant protein folding and secretion in Pichia pastoris

Abstract: The development of Pichia pastoris as a production platform for recombinant proteins has been a remarkable success story over the last three decades. Stable cheap production processes and the good protein secretion abilities were pacemakers of this development. However, limitations of protein folding, glycosylation or secretion have been identified quite early on. With the availability of genome sequences and the development of systems biology characterization in the last 5 years, remarkable success in strain … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
108
0

Year Published

2015
2015
2020
2020

Publication Types

Select...
6
2

Relationship

1
7

Authors

Journals

citations
Cited by 137 publications
(110 citation statements)
references
References 116 publications
2
108
0
Order By: Relevance
“…Existing shortcomings of the P. pastoris production system are addressed either by genetic strain engineering (Idiris et al, 2010, Puxbaum et al, 2015 or at the level of the cultivation process in bioreactors. Generally, bioprocess design aims at identifying optimum conditions for biomass growth and product formation, including pH, temperature, oxygen and nutrient supply [e.g.…”
Section: Introductionmentioning
confidence: 99%
“…Existing shortcomings of the P. pastoris production system are addressed either by genetic strain engineering (Idiris et al, 2010, Puxbaum et al, 2015 or at the level of the cultivation process in bioreactors. Generally, bioprocess design aims at identifying optimum conditions for biomass growth and product formation, including pH, temperature, oxygen and nutrient supply [e.g.…”
Section: Introductionmentioning
confidence: 99%
“…Furthermore, this yeast can be engineered to mimic the human N -glycosylation pathway and specific types of O -glycosylation, becoming a potential alternative for mammalian cell culture for the production of recombinant therapeutic glycoproteins for human use [4, 5]. Overexpression of heterologous proteins can lead to saturation or overloading of the secretory pathway [6, 7]. The most important bottlenecks in terms of recombinant protein production and secretion are membrane translocation, signal peptide processing and folding within the endoplasmic reticulum (ER) [8].…”
Section: Introductionmentioning
confidence: 99%
“…[92] Yeasts combine the simplicity, low cost, ease of manipulation and short generation time of a unicellular organism with the ability to carry complex post-translational modifications, [93] including human-like protein glycosylation in engineered strains. [94] Saccharomyces cerevisiae and Pichia pastoris are the best characterized species, with glycoengineered strains of the latter shown to be capable of producing recombinant anti-human epidermal growth factor receptor 2 (HER2) antibodies similar to the FDA-approved and mammalian cellproduced trastuzumab used to treat metastatic breast cancer. [95] Insect cells possess eucaryotic protein expression and posttranslational modification machineries typical of mammalian cells.…”
Section: Expression Systems For Recombinant Productsmentioning
confidence: 99%